Turning high potential into high performance.
We are a specialist venture investor with a focus on science and technology companies that are posed for rapid growth.
We invest in sectors where innovation is driving exponential growth, and global demand.
We invest in companies with breakthrough technologies & strong leadership, who are on the cusp of a significant value inflection event.
We deploy the capital, resource and expertise required to mitigate risk and accelerate commercial success.
Our Investment Philosophy
Deploy Smart Capital Focused on Value Creation, Syndication and Global Exit.
The UK develops some of the most advanced and innovative technologies in the world, especially in cutting-edge sectors such as life sciences, Al and robotics. However, many of these technologies fail to demonstrate their true commercial potential due to a scarcity of capital, experience, and resources during early commercialisation stages.
We believe that significant value can be created by investing at this stage, if the appropriate expertise, resources and network can be deployed to nurture the SME through to commercial success.
Guided by a highly experienced investment committee and leading scientific advisory board, NCL have deployed over $55M into the health sector, as a lead investor, over the last 3 years.
We believe that early-stage, high potential SMEs will benefit immensely from a physical cluster of like-minded entrepreneurs and organisations.
Our premier life science cluster is Discovery Park, the ex-Pfizer R&D site that has attracted over a hundred high-potential SMEs. The Park has not only premium office facilities and comprehensive service providers on site, but also cutting-edge laboratory facilities that are normally hard to access for small companies. These facilities are always open to our investee companies when needed, with room to scale up as the companies grow.
Our team spans three generations and is vastly experienced in venture investment, fund structuring, entrepreneurship and business management and is supported by an expert Scientific Advisory Board.
David Vintiner Surgeon Charles Nduka has developed sensor tech to track facial expressions and is currently using it with patients with Parkinson’s. His next … Continued
Trinity College’s new spin-out organisation, Azadyne, has completed a £1.5million funding round for its new approach to the treatment of autoimmune diseases. The Kent … Continued
IT HAS been a professional crusade against deadly illness – and the scourge of cancer in particular – that has been marked at intervals … Continued
– The first completed bio-banks will be used to develop more cost-effective, safe and efficacious cancer treatments – Funding provided by European Horizon 2020 … Continued